MIBG

Henry Repeating Arms Donates 50 Engraved and Hand-Painted Rifles for 8-Year-Old Girl's Cancer Treatments

Retrieved on: 
Thursday, September 28, 2023
Human, Radiation, Face, Friends, Bone marrow, Flower, Attention, Immunotherapy, Firearm, Motion, Gold, MIBG, Henry, Diagnosis, RICE, Courage, Hand, Family, Telescopic sight, Gunsmith

The rifles are available online, and all proceeds will be presented to the family of 8-year-old Kaia Lauro to provide direct financial relief for mounting medical expenses.

Key Points: 
  • The rifles are available online, and all proceeds will be presented to the family of 8-year-old Kaia Lauro to provide direct financial relief for mounting medical expenses.
  • Kaia was diagnosed with Stage 4 Neuroblastoma in 2019, a rare childhood cancer that formed in her adrenal gland and later spread to her bone and bone marrow.
  • Since diagnosis, Kaia has undergone countless chemotherapy treatments, painful immunotherapy sessions, Metaiodobenzylguanidine (MIBG) radiation, focused radiation, stem cell infusions, and blood transfusions.
  • To learn more about Henry Repeating Arms and its products, visit henryusa.com .

Children’s Hospital Los Angeles Offers MIBG Therapy for Neuroblastoma

Retrieved on: 
Thursday, July 14, 2022
Oncology, Nursing, Education, Health, Hospitals, Radiology, Training, Blog, U.S. News & World Report, Radiation, Hematology, Multimedia, Child, Keck School of Medicine of USC, I-131, YouTube, LinkedIn, Travel, Food and Drug Administration, Patient, Medicine, MD, Instagram, Â, Radioactive decay, Food, Organ transplantation, Parent, Physician, Facility, USC, Brain, National Institutes of Health, Children's Hospital Los Angeles, New Approach, Hospital, Pediatrics, MS, Randomized controlled trial, News, Iodine, Twitter, Southwestern United States, Immunotherapy, Children and Family Court Advisory and Support Service, National, Medical imaging, Pharmaceutical industry, MIBG, Cancer, Facebook, Neuroblastoma

View the full release here: https://www.businesswire.com/news/home/20220714005155/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20220714005155/en/
    Childrens Hospital Los Angeles offers MIBG Therapy for Neuroblastoma (Photo: Business Wire)
    MIBG (metaiodobenzylguanidine) is a compound that was once a blood pressure medicine and is easily absorbed by neuroblastoma cells.
  • Bringing MIBG therapy to Childrens Hospital Los Angeles will allow many more patients to access this promising treatment, says Araz Marachelian, MD, MS , Director of the Neuroblastoma Program in the Cancer and Blood Disease Institute at Childrens Hospital Los Angeles.
  • That phase 1 trial is led by the New Approaches to Neuroblastoma Therapy (NANT) consortium, which is headquartered at Childrens Hospital Los Angeles.
  • Founded in 1901, Childrens Hospital Los Angeles is the largest provider of care for children in Los Angeles County.

Y-mAbs Announces Naxitamab Chemoimmunotherapy Investigational Trial for High-Risk Neuroblastoma Meets Primary Endpoint

Retrieved on: 
Thursday, May 26, 2022
Memorial Sloan Kettering Cancer Center, Humanized antibody, Government, Naxitamab, Hospital Sant Joan de Déu Barcelona, Omicron, Aplastic anemia, Private Securities Litigation Reform Act, SEC, CR, Cancer, Risk, Interim, Annual report, Pain, Toxic shock syndrome, MSK, Therapy, ORR, Clinical trial, B7-H3, COVID-19, Failure, Marketing, Research, PR, MIBG, Growth, Diarrhea, GLOBE, Company, Coronavirus, Bone marrow, American Society of Clinical Oncology, FDA, MD, Neoplasm, Patient, Febrile neutropenia, Society, Industry, HITS, Safety, GM-CSF, GD2, Hypertension, Medical imaging, Pharmaceutical industry, Temozolomide, Irinotecan, Delta

Health authorities have not established the safety and efficacy of the HITS protocol, as it is investigational and has not been approved by health authorities.

Key Points: 
  • Health authorities have not established the safety and efficacy of the HITS protocol, as it is investigational and has not been approved by health authorities.
  • The primary endpoint of the phase 2 trial at MSK was complete response (CR) and partial response (PR) after 4 cycles.
  • The primary endpoint was reached in the MSK phase 2 trial: Objective Response Rate (ORR) according to the International Neuroblastoma Response Criteria (INRC) of 30.6 %, with a lower boundary of 20.4%.
  • In the MSK phase 2 trial, the ORR was 64% for all patients, with soft tissue (48%) and skeletal MIBG uptake (66%).